首页|Epigenetic modification in liver fibrosis:Promising therapeutic direction with significant challenges ahead

Epigenetic modification in liver fibrosis:Promising therapeutic direction with significant challenges ahead

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Liver fibrosis,characterized by scar tissue formation,can ultimately result in liver failure.It's a major cause of morbidity and mortality globally,often associated with chronic liver diseases like hep-atitis or alcoholic and non-alcoholic fatty liver diseases.However,current treatment options are limited,highlighting the urgent need for the development of new therapies.As a reversible regulatory mechanism,epigenetic modification is implicated in many biological processes,including liver fibrosis.Exploring the epigenetic mechanisms involved in liver fibrosis could provide valuable insights into developing new treatments for chronic liver diseases,although the current evidence is still controversial.This review pro-vides a comprehensive summary of the regulatory mechanisms and critical targets of epigenetic modifi-cations,including DNA methylation,histone modification,and RNA modification,in liver fibrotic diseases.The potential cooperation of different epigenetic modifications in promoting fibrogenesis was also highlighted.Finally,available agonists or inhibitors regulating these epigenetic mechanisms and their potential application in preventing liver fibrosis were discussed.In summary,elucidating specific drug-gable epigenetic targets and developing more selective and specific candidate medicines may represent a promising approach with bright prospects for the treatment of chronic liver diseases.

Liver fibrosisEpigenetics regulationDNA methylationHistone acetylationHistone methylationmRNA methylationNon-coding RNADrug development

Runping Liu、Yajing Li、Qi Zheng、Mingning Ding、Huiping Zhou、Xiaojiaoyang Li

展开 >

School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 102400,China

School of Life Sciences,Beijing University of Chinese Medicine,Beijing 102400,China

Department of Microbiology and Immunology,Virginia Commonwealth University,Richmond,VA 22460,USA

National Key Research and Development Program on Modernization of Traditional Chinese MedicineNational High-Level Talents Special Support Program to Xiaojiaoyang Li(China)中央高校基本科研业务费专项Huiping Zhou is a VA Research Career ScientistHuiping Zhou is a VA Research Career Scientist

2022YFC35021042023-JYB-JBZD-046IK6BX004477USA

2024

10.1016/j.apsb.2023.10.023

药学学报(英文版)

药学学报(英文版)

CSTPCD
ISSN：
年,卷(期)：2024.14(3)
  • 183